May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Photodynamic Therapy With Verteporfin Combined With Intravitreal Injection of Ranibizumab for Occult and Classic CNV in AMD
Author Affiliations & Notes
  • M. M. Maier
    Ophthalmology, Technical University of Munich, Munich, Germany
  • N. Feucht
    Ophthalmology, Technical University of Munich, Munich, Germany
  • B. Fiore
    Ophthalmology, Technical University of Munich, Munich, Germany
  • C. Winkler von Mohrenfels
    Ophthalmology, Technical University of Munich, Munich, Germany
  • C. Fegert
    Ophthalmology, Technical University of Munich, Munich, Germany
  • P. Kook
    Ophthalmology, Technical University of Munich, Munich, Germany
  • C. P. Lohmann
    Ophthalmology, Technical University of Munich, Munich, Germany
  • Footnotes
    Commercial Relationships  M.M. Maier, None; N. Feucht, None; B. Fiore, None; C. Winkler von Mohrenfels, None; C. Fegert, None; P. Kook, None; C.P. Lohmann, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 269. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. M. Maier, N. Feucht, B. Fiore, C. Winkler von Mohrenfels, C. Fegert, P. Kook, C. P. Lohmann; Photodynamic Therapy With Verteporfin Combined With Intravitreal Injection of Ranibizumab for Occult and Classic CNV in AMD. Invest. Ophthalmol. Vis. Sci. 2008;49(13):269. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To discuss the effect and outcome of a combined photodynamic therapy and intravitreal injection of ranibizumab (0.5 mg) in occult CNV with recent disease progression and in classic choroidal neovascularisation (CNV) due to AMD.

Methods: : In a pilot study in 25 patients (18 classic, 7 occult CNV) intravitreal injection of ranibizumab was administered within 12 to 24 hours after standard PDT, followed by 2 injections of ranibizumab after 1 and 2 months. Before, 3 and 6 month after treatment visual acuity, OCT examinations (retinal thickness) and fluorescein angiography were performed.

Results: : Mean visual acuity was significantly improved compared to baseline. (VA baseline 20/80, after 3 month 20/50, and 20/63 after 6 month). We found no choroidal hypoperfusion and no RPE rip. OCT-findings and fluorescein angiography in patients with occult and classic choroidal neovascularisation 3 and 6 month after combination therapy showed a reduced retinal thickness (baseline: 241µm, after 3 month: 205µm and after 6 month 232µm) and reduction of leakage compared to baseline.

Conclusions: : Photodynamic therapy combined with injection of intravitreal ranibizumab was well tolerated and tends to be more effective compared to ranibizumab mono-therapy. Our short term results are very promising. Further studies are necessary to show the long term effect of PDT and Anti-VEGF combination therapy.

Keywords: age-related macular degeneration • vascular endothelial growth factor • vitreous 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×